Establishment Labs Holdings Inc. (NASDAQ:ESTA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been assigned a consensus rating of “Moderate Buy” from the nine brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $98.3750.

A number of analysts have commented on ESTA shares. TD Cowen lifted their target price on Establishment Labs from $95.00 to $117.00 and gave the stock a “buy” rating in a report on Monday. Citigroup upped their price target on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. BTIG Research increased their price objective on Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a research report on Thursday. Canaccord Genuity Group set a $105.00 price objective on Establishment Labs in a report on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th.

Institutional Investors Weigh In On Establishment Labs

Large investors have recently added to or reduced their stakes in the stock. KBC Group NV purchased a new position in Establishment Labs in the first quarter worth about $28,000. Quarry LP purchased a new stake in shares of Establishment Labs during the 3rd quarter valued at about $34,000. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs in the 4th quarter worth approximately $47,000. Osaic Holdings Inc. lifted its stake in shares of Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares during the period. Finally, State of Wyoming purchased a new position in shares of Establishment Labs in the second quarter worth approximately $87,000. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Trading Down 13.4%

Establishment Labs stock opened at $79.05 on Friday. Establishment Labs has a 12 month low of $33.35 and a 12 month high of $97.59. The company has a current ratio of 2.96, a quick ratio of 1.91 and a debt-to-equity ratio of 16.82. The business’s fifty day simple moving average is $86.29 and its two-hundred day simple moving average is $74.23. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -53.05 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). The firm had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s revenue for the quarter was up 31.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.57) EPS. As a group, equities analysts predict that Establishment Labs will post -1.07 earnings per share for the current fiscal year.

Establishment Labs News Summary

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: BTIG Research raised its price target to $103 from $96 and maintained a “buy” rating, implying substantial upside from the referenced share price. Benzinga article
• Positive Sentiment: Needham increased its price target to $95 from $86 and reiterated a “buy” rating, signaling continued analyst confidence in Establishment Labs’ growth outlook. StreetInsider article
• Positive Sentiment: Second-quarter revenue increased 31.7% year over year to $67.54 million, exceeding analysts’ $65.79 million estimate. The company also projected fiscal 2026 revenue of $269 million to $271 million, above the $267.5 million consensus forecast. Zacks article
• Neutral Sentiment: Management discussed the quarter and outlook during the Q2 2026 earnings call, providing additional context for investors evaluating the company’s growth plans and path toward profitability. Q2 2026 earnings call transcript
• Negative Sentiment: Establishment Labs reported a $0.39 quarterly loss per share, wider than the expected $0.34 loss, although it improved from a $0.57 loss in the prior-year quarter. Ongoing losses and negative profitability metrics likely weighed on the stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.